Skip to main content
. 2017 Aug 15;313(6):E631–E640. doi: 10.1152/ajpendo.00146.2017

Fig. 2.

Fig. 2.

Effects of glucose tolerance and body mass index on soluble receptor for advanced glycation end products (sRAGE) isoforms. Subject groups were collapsed into normal glucose tolerance (NGT) vs. impaired glucose tolerance-type 2 diabetes mellitus (IGT-T2DM) designations and further stratified by body mass index (lean vs. overweight-obese). Lean, NGT, n = 74; overweight-obese, NGT, n = 76; lean, IGT-T2DM, n = 16; overweight-obese, IGT-T2DM, n = 105. Group comparisons were made for total sRAGE (A), cleaved RAGE (cRAGE; B), endogenous secretory RAGE (esRAGE; C), and cRAGE:esRAGE ratio (D) using two-way ANOVA and Bonferroni post hoc tests as necessary. Bars represent means ± SD. **P < 0.01 and ***P < 0.0001 vs. NGT; #P < 0.05, ##P < 0.01, and ###P < 0.0001 vs. lean.